Loyal vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Loyal is a veterinary biotech developing FDA-regulated longevity drugs for dogs; its lead drug LOY-001 received FDA reasonable expectation of effectiveness — the first longevity drug for any species to do so; raised $45M; founded by Celine Halioua.
About
Loyal is a veterinary biotechnology company founded in 2020 by Celine Halioua and headquartered in San Francisco, California. The company is developing pharmaceutical treatments designed to extend the healthspan and lifespan of dogs — large breeds in particular, which age faster and live shorter lives than small breeds. Loyal's approach is grounded in the biology of aging: targeting the hormonal, metabolic, and cellular mechanisms that drive age-related decline in dogs, with the goal of creating FDA-approved drugs that add healthy years to companion animals' lives.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.